Federal heat on UnitedHealth sends shares tumbling — what you need to know
UnitedHealth DOJ probe impacts stock value as federal heat intensifies on the healthcare giant. The U.S. Justice Department has launched both criminal and civil investigations into UnitedHealth's Medicare Advantage billing practices, raising serious concerns about possible overcharging. As news broke, UnitedHealth's stock plunged over 4%, deepening a year-long 40% decline. Investors are now worried about future earnings, rising healthcare costs, and tighter regulations. UnitedHealth says it's cooperating fully and reviewing its billing system. With leadership changes and legal pressure mounting, this story is a must-read for anyone watching the healthcare or stock market space right now.
UnitedHealth Group (NYSE: UNH) stock has lost over 40% of its value in 2025, wiping out more than $120 billion in market capitalization. The latest blow came after the healthcare giant confirmed it is under criminal and civil investigation by the U.S. Department of Justice (DOJ) over its Medicare Advantage billing practices, sending shares tumbling nearly 4% in pre-market trading. With rising medical costs, shaken investor confidence, and leadership upheaval, UnitedHealth's dramatic decline marks one of the worst performances among S&P 500 stocks this year. UnitedHealth Group Inc. (NYSE: UNH) saw its stock tumble nearly 4% today, continuing a steep downward spiral that has erased over 40% of its value in 2025 alone. The latest drop comes after the company confirmed that it's under both criminal and civil investigation by the U.S. Department of Justice (DOJ), related to its Medicare Advantage billing practices. UnitedHealth stock has been among the worst performers on the S&P 500 this year. After starting 2025 near $525 per share, the stock has plummeted below $300, marking a more than 40% year-to-date drop.
Key moments behind the plunge: April 2025 : Stock dropped 22% in a single day after missing Q1 earnings and slashing full-year guidance.
: Stock dropped after missing Q1 earnings and slashing full-year guidance. May 2025 : CEO Andrew Witty resigned, adding leadership instability to the mix.
: CEO Andrew Witty resigned, adding leadership instability to the mix. July 2025: Confirmation of DOJ investigation triggers renewed selling pressure.
The Department of Justice (DOJ) is officially investigating UnitedHealth Group—America's largest health insurer—over its Medicare Advantage billing. The federal probes focus on whether the company artificially inflated patient risk scores to receive higher reimbursements from the government. UnitedHealth has confirmed receiving requests for information from the DOJ and stated it is cooperating fully with both criminal and civil investigations. While the company initially denied any criminal probe, it now admits it had proactively reached out to federal authorities earlier this year to clarify billing procedures and launch internal reviews.
The DOJ's primary concern is centered on risk adjustment coding—a process that determines how much money the federal government pays insurers like UnitedHealth based on patients' medical conditions. Allegations suggest the company may have exaggerated diagnoses to collect excess payments from Medicare.
As soon as news of the investigation surfaced, UnitedHealth stock took a hit. Shares fell over 4% in premarket trading, extending a broader decline that's seen the stock drop more than 40% year-to-date.
This is not an isolated event. Earlier this year, UnitedHealth's stock experienced a major downturn when its former CEO unexpectedly resigned and the company withdrew its 2025 earnings guidance, citing cost overruns tied to its Medicare Advantage business. The current legal troubles are piling onto existing financial pressures, sending a clear message to investors: the road ahead may be rocky. At the heart of the investigation is Medicare Advantage, a privately managed health insurance program funded by the federal government. Insurers like UnitedHealth receive payments based on the health risk profiles of their enrollees. The more serious the health conditions of a patient, the higher the risk score—and the larger the government payout. However, the DOJ is now investigating whether UnitedHealth manipulated these scores by inflating patient diagnoses. This isn't a new concern in the industry. Other insurers have faced similar audits and lawsuits. However, given UnitedHealth's size and influence, the implications could be significantly larger. This is the big question facing investors. UNH stock may look cheap relative to historical valuation, but headline risk remains high. Here are two opposing scenarios:
Bull Case: DOJ investigation ends with a manageable settlement.
Medical cost inflation stabilizes.
Leadership transition brings strategic clarity. Bear Case: Legal issues expand and trigger major fines or contract losses.
Costs continue rising, forcing more earnings cuts.
Institutional investors exit further, adding pressure.
In response to the federal heat, UnitedHealth has taken several steps to present itself as compliant and transparent: Voluntary Disclosures : The company claims it initiated contact with the DOJ months ago and is cooperating with all requests.
: The company claims it initiated contact with the DOJ months ago and is cooperating with all requests. Third-party Audits : UnitedHealth says it is conducting external reviews of its risk adjustment processes, possibly signaling internal reforms are underway.
: UnitedHealth says it is conducting external reviews of its risk adjustment processes, possibly signaling internal reforms are underway. Compliance Enhancements: The insurer is working on strengthening its internal controls to ensure billing accuracy going forward. Despite these efforts, legal experts suggest that even if no wrongdoing is found, the very existence of a federal investigation could lead to increased regulatory oversight, reputational damage, and mounting legal expenses. The DOJ probe comes at a time when UnitedHealth is already navigating several internal and external challenges: In May, longtime CEO Andrew Witty stepped down unexpectedly amid the growing storm. Former CEO Stephen Hemsley returned to stabilize the company and restore investor trust. Healthcare utilization surged in recent quarters, leading to higher-than-expected medical costs. UnitedHealth has warned of increased pressure on margins due to greater demand for surgeries, outpatient care, and chronic condition treatments. Alongside regulatory attention, UnitedHealth is facing public scrutiny. If the DOJ finds grounds for prosecution, the company could face heavy fines, tighter compliance mandates, or even restrictions on future government contracts. For investors, the combination of legal risk, leadership uncertainty, and financial strain creates a complex risk profile. Shareholder Value : With shares down over 40% YTD, portfolio exposure is already taking a hit.
: With shares down over 40% YTD, portfolio exposure is already taking a hit. Earnings Outlook : With the company pulling its 2025 forecast, investors are left without clarity on future earnings potential.
: With the company pulling its 2025 forecast, investors are left without clarity on future earnings potential. Regulatory Uncertainty: Prolonged investigations may drag down sentiment and stock performance even if no wrongdoing is proven. While some see the current dip as a buying opportunity in a fundamentally strong company, others warn that further volatility is likely in the coming quarters. Earnings Report (Early August) : Investors are eagerly awaiting the next quarterly results. The focus will be on legal disclosures, medical cost trends, and updated guidance.
: Investors are eagerly awaiting the next quarterly results. The focus will be on legal disclosures, medical cost trends, and updated guidance. DOJ Progress Updates : Any new details about the investigation's scope, possible subpoenas, or charges could further affect stock movement.
: Any new details about the investigation's scope, possible subpoenas, or charges could further affect stock movement. Organizational Changes: Investors will also watch for more leadership reshuffles or board-level changes aimed at regaining market trust. The UnitedHealth DOJ investigation is a serious matter—not just for the company, but for the broader health insurance industry. While the company has made moves toward transparency and reform, the federal probe introduces significant uncertainty around both earnings and regulatory compliance. If you're an investor, this is a moment to remain informed and cautious. Watching how the company navigates the legal, financial, and reputational fallout will be critical in determining whether UnitedHealth can regain its footing—or if deeper troubles lie ahead.
Q1: Why is UnitedHealth under DOJ investigation? The DOJ is probing UnitedHealth for possibly overbilling Medicare Advantage through inflated diagnoses.
Q2: How did the DOJ probe affect UnitedHealth stock? UnitedHealth stock fell sharply after the DOJ launched its criminal and civil investigations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fibre2Fashion
an hour ago
- Fibre2Fashion
Bangladesh's economic outlook stable; revenue generation too low: S&P
Bangladesh's fiscal deficit will hold roughly stable over the next three years at about 4.6 per cent of the gross domestic product (GDP), according to S&P Global Ratings, which recently said the country's net general government debt remains moderate. It estimates that the net general government debt will average about 35 per cent of the GDP till fiscal 2027-28 (FY28). However, the country's public interest burden is high, at about 26 per cent of revenues. Bangladesh's fiscal deficit will hold roughly stable over the next three years at about 4.6 per cent of the GDP, S&P Global Ratings has said. The country's net general government debt remains moderate. Though its economic outlook stable, revenue generation is critically low as a share of the economy. The real growth rate per capita will remain quite strong compared to that of the country's peers. Following improvements in Bangladesh's official foreign-exchange reserves, S&P Global Ratings recently affirmed the country's long-term sovereign credit rating at B+ and short-term rating at B, while calling its economic outlook stable. This reflects the real growth rate per capita will remain quite strong compared to that of the country's peers, it noted. The macroeconomic policies enacted over the past 18 months, such as transitioning to a more flexible exchange rate regime, allowing the local currency to depreciate, and tightening the monetary policy, are helping build foreign exchange liquidity, it said in a note. But the country faces heightened trade risk from relatively high US tariffs, it cautioned. The country's real economic growth rate, which decelerated meaningfully over the past two years, may pick up the pace if political and external stability solidifies over the next 12 months, according to the rating agency. It said annual growth should accelerate to about 6.1 per cent in the next three years if these conditions materialise as the economy bounces back from the 2024 political crisis. Bangladesh's uncertain political landscape may constrain the effectiveness of its institutions and policy certainty in the near term until a more lasting solution emerges, it observed. The US tariff rate of 35 per cent, which will potentially apply to Bangladeshi imports from August 1, could affect labour market conditions if the two countries fail to reach a more effective agreement, S&P Global Ratings said. Modest per capita income, which it estimates at about $2,620 in the fiscal year ending in June 2025, remains one of the main constraints for Bangladesh's rating. It also said Bangladesh's interest burden is elevated, especially relative to the government's very low revenue collection. Besides, the country relies entirely on official bilateral and multilateral partners for its foreign currency borrowing, which partially mitigates risks to its debt profile. Monetary and external policy reforms undertaken by the Bangladesh Bank are helping restore the country's external stability, it said. Bangladesh's narrow revenue base constrains the government's flexibility to provide fiscal support in times of stress, it noted. Revenue generation remains critically low as a share of the economy and when benchmarked against other sovereigns, it added. Fibre2Fashion News Desk (DS)
Economic Times
an hour ago
- Economic Times
Fed likely to hold steady, but September rate cut hopes hinge on data: Seth R Freeman
So, it is positive. It is actually very much related to enthusiasm for AI and the efficiencies coming from AI. "The other aspect that the Fed is looking at is employment rates. So, there is a possibility, the Fed is certainly getting a lot of pressure from the administration, but the chairman has been quite clear that that they are characteristically looking at data and so it may be a little too early. It kind of depends how things look here in the US right after Labour Day," says Seth R Freeman, GlassRatner Advisory. Tell us there are a lot of cues to watch out for as far as Wall Street is concerned, we have a lot of earnings coming out. We also have the important FOMC meet. Now, most of us are expecting the rates to be held steady and the Fed has conveyed this in no uncertain terms despite the pressure coming in from the Trump government. But it is really the commentary that we will be watching out for the hopes of a rate cut perhaps in the month of September. Is that on the cards? Is that talk going to be on the table? Seth R Freeman: Well, that the situation may be, the viewpoint may change now that the deal has been struck with the EU and this concern about what the real effect of tariffs would be here on the US economy. The other aspect that the Fed is looking at is employment rates. So, there is a possibility, the Fed is certainly getting a lot of pressure from the administration, but the chairman has been quite clear that that they are characteristically looking at data and so it may be a little too early. It kind of depends how things look here in the US right after Labour Day. Let us also talk about the IT sector if you could. Now in the US all these major tech companies including the likes of Meta, Microsoft, Amazon they are going to report their earnings this week. So, first up, what is your expectation there and also if you could help us with your stance on the Indian IT sector given the kind of slowdown that we have seen and we are also hearing about workforce cutting, the announcements coming in from TCS. So, what kind of impact do you see from the AI spending going up? Seth R Freeman: Well, at the end of last week, Google was indicating that its business is very robust and really starting to get some payback from AI and there has been a concern that AI would and the fact that you can do searching for example and you get an AI result that maybe you do not have to dig around for different links and that is going to hurt advertising revenue. But I am actually expecting the earnings announcements to be fairly positive across the sector. Certainly, investors think it is going to be positive because look at the gains we have had in the S&P 500 and the Nasdaq. So, it is positive. It is actually very much related to enthusiasm for AI and the efficiencies coming from AI.
Business Standard
an hour ago
- Business Standard
Barometers pare losses; Nifty trades above 24,850
The headline equity benchmarks pared all early losses and traded with minor gains in the morning trade. The Nifty traded above the 24,850 mark. Realty shares witnessed selling pressure for the fifth consecutive trading session. At 10:30 IST, the barometer index, the S&P BSE Sensex rose 57.70 points or 0.08% to 81,517.51. The Nifty 50 index added 31.40 points or 0.12% to 24,864.85. In the broader market, the S&P BSE Mid-Cap index rallied 0.60% and the S&P BSE Small-Cap index rose 0.24%. The market breadth was positive. On the BSE 2,028 shares rose and 1,664 shares fell. A total of 209 shares were unchanged. Economy: India's forex reserves dipped by $1.18 billion to $695.49 billion for the week ending July 18, data by the Reserve Bank of India showed on Friday. For the week ended July 18, foreign currency assets, a major component of the reserves, slipped by $1.201 billion to $587.609 billion, the data released on Friday showed. However, the gold reserves increased by $150 million to $84.499 billion during the week, the RBI said. The Special Drawing Rights (SDRs) were down by $119 million to $18.683 billion, the apex bank said. India's reserve position with the IMF declined by $13 million to $4.698 billion in the reporting week, the apex bank data showed. Result today: Adani Green Energy (up 2.12%), Apollo Micro Systems (down 2.15%), Indusind Bank (down 0.45%), Mazagon Dock Shipbuilders (down 0.75%), JK Paper (down 1.62%), KEC International (up 0.83%), Laxmi Organic Industries (up 0.12%), Mold-Tek Packaging (up 0.95%), Motherson Sumi Wiring India (down 1.01%), NTPC Green Energy (up 2.17%), Paradeep Phosphates (up 5.35%), Piramal Pharma (up 1.06%), Quess Corp (down 0.84%), RailTel Corporation of India (down 1.64%), Sanghi Industries (up 0.39%), Transport Corporation of India (down 1.37%), Thangamayil Jewellery (up 0.46%), Torrent Pharmaceuticals (down 0.09%), TTK Prestige (up 0.08%), UPL (up 0.18%) and Vijaya Diagnostic Centre (up 0.92%) will announce their quarterly results later today. Buzzing Index: The Nifty Realty index dropped 2.90% to 923.05. The index slumped 8.26% in five consecutive trading sessions. Lodha Developers (down 4.37%), DLF (down 2.8%), Prestige Estates Projects (down 2.24%), Brigade Enterprises (down 1.77%), Phoenix Mills (down 1.64%), Oberoi Realty (down 1.55%), Raymond (down 1.25%), Godrej Properties (down 1.24%) and Sobha (down 0.88%) declined. Stocks in Spotlight: ACME Solar Holdings surged 9.16% after the companys consolidated net profit stood at Rs 130.83 crore in Q1 FY26, steeply higher than Rs 1.39 crore in Q1 FY25. Revenue from operations jumped 65% YoY to Rs 510.98 crore in Q1 June 2025. Reliance Infrastructure advanced 2.32% after the company reported a consolidated net profit of Rs 59.84 crore in Q1 FY26, compared to a net loss of Rs 233.74 crore posted in Q1 FY25. Revenue from operations fell 17.86% to Rs 5,907.82 crore in the quarter ended 30 June 2025.
